ABO-101

DRUG3 trials

Sponsors

Arbor Biotechnologies Inc., Abeona Therapeutics, Inc, Arbor Biotechnologies

Conditions

Mucopolysaccharidosis III-BPrimary Hyperoxaluria Type 1 (PH1)

Phase 1

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

RecruitingNCT06839235

Arbor BiotechnologiesPrimary Hyperoxaluria Type 1 (PH1)

Start: 2025-06-16End: 2043-02-01Target: 23Updated: 2026-02-12

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants with Primary Hyperoxaluria Type 1 (PH1)

RecruitingCTIS2024-518144-20-00

Arbor Biotechnologies Inc.Primary Hyperoxaluria Type 1 (PH1)

Start: 2025-09-03Target: 6Updated: 2026-01-26

Unknown Phase

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

TerminatedNCT04655911

Abeona Therapeutics, IncMucopolysaccharidosis III-B

Start: 2020-10-28End: 2022-04-07Updated: 2022-05-31